PRCTNGMHealthcare·Medical Devices#34 in industry

PROCEPT BioRobotics Corporation

Reports in 2d· 2026-04-29

-19.8% · 90d

$24.09

-0.27 (-1.11%)

News

(1)

April 2026

Apr 22, 20266 days agoDEF 14AHealthcare

PROCEPT votes on directors, auditor, and executive compensation at 2026 meeting

PRCTPROCEPT BioRobotics Corp

# 📜 What This Document Is 📄 This document is a Proxy Statement (Form DEF 14A). Think of it like a formal instruction manual for an Annual Meeting of Stockholders. It doesn't report on quarterly earnings, but rather informs shareholders about the foundational rules and decisions of the company. It

Read summaryView on SEC EDGAR

Key Data

Market Cap$1.37B

Open$24.30

Prev Close$24.36

Day Range$23.91 – $25.14

52W Range$19.35 – $66.85

Volume1,183,353

P/E (TTM)—

EPS$-1.72

Dividend Yield—

Beta0.93

Profit Margin-31.02%

Revenue Growth11.90%

Price Target$30.11(+25.0%)

Next Earnings2026-04-29(2d)

Analyst Ratings

Buy12 analysts

Buy 7Hold 4Sell 1

About

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Healthcare · Medical Devices

888 employees

www.procept-biorobotics.com